Latest news

• Sanofi’s latecomer PD-1 gets date for FDA verdict

  The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... Regeneron-partnered cemiplimab is the first of the

• Sanofi’s PD-1 inhibitor starts EU review for skin cancer

  Sanofi’ s PD-1 inhibitor starts EU review for skin cancer. Cemiplimab could be the first PD-1-targeting drug approved for CSCC. ... As of yet, none of the other PD-1/PD-L1-targeting drugs are approved for CSCC.

• Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

  CSCC is the second deadliest skin cancer after melanoma, and while quite treatable if caught early it is very serious in the advanced stages. ... Advanced CSCC is responsible for 3, 900 to 8, 800 deaths per year in the US, ”said Regeneron’s clinical